v3.26.1
Organization and Principal Activities - Schedule of Consolidated Financial Statements Reflect the Activities (Details)
 6 Months Ended
Mar. 31, 2026
Work BVI [Member]  
Subsidiaries  
Date of incorporation /acquisition Mar. 15, 2022
Place of incorporation British Virgin Islands (“BVI”)
Percentage of effective ownership 100.00%
Principal Activities Investment holding
Work Medical Technology [Member]  
Subsidiaries  
Date of incorporation /acquisition Apr. 19, 2022
Place of incorporation Hong Kong
Percentage of effective ownership 100.00%
Principal Activities Investment holding
Work RWA TECH LIMITED [Member]  
Subsidiaries  
Date of incorporation /acquisition Sep. 02, 2025
Place of incorporation Hong Kong
Percentage of effective ownership 100.00%
Principal Activities Investment holding
WFOE [Member]  
Subsidiaries  
Date of incorporation /acquisition Apr. 28, 2022
Place of incorporation PRC
Percentage of effective ownership 100.00%
Principal Activities Investment holding
Work Hangzhou [Member]  
Subsidiaries  
Date of incorporation /acquisition Nov. 10, 2021
Place of incorporation PRC
Percentage of effective ownership 100.00%
Principal Activities Investment holding
Hangzhou Shanyou [Member]  
Subsidiaries  
Date of incorporation /acquisition Apr. 29, 2002
Place of incorporation PRC
Percentage of effective ownership 95.00%
Principal Activities Produce and sale of medical consumables
Hangzhou Hanshi [Member]  
Subsidiaries  
Date of incorporation /acquisition Jul. 22, 2019
Place of incorporation PRC
Percentage of effective ownership 60.00%
Principal Activities Sale of medical consumables
Shanghai Saitumofei Medical Treatment Technology Co., Ltd. (“Shanghai Saitumofei”) [Member]  
Subsidiaries  
Date of incorporation /acquisition Jul. 27, 2022 [1]
Place of incorporation PRC [1]
Percentage of effective ownership 57.5317% [1]
Principal Activities Sale of medical consumable [1]
Hunan Saitumofei Medical Treatment Technology Co., Ltd (“Hunan Saitumofei”) [Member]  
Subsidiaries  
Date of incorporation /acquisition Jul. 27, 2022
Place of incorporation PRC
Percentage of effective ownership 100.00%
Principal Activities Sale of medical consumables
Hangzhou Woli Medical Treatment Technology Co., Ltd (“Hangzhou Woli”) [Member]  
Subsidiaries  
Date of incorporation /acquisition Jul. 22, 2022
Place of incorporation PRC
Percentage of effective ownership 100.00%
Principal Activities Sale of medical consumables
Hangzhou Youshunhe Technology Co., Ltd. (“Hangzhou Youshunhe”) [Member]  
Subsidiaries  
Date of incorporation /acquisition Feb. 27, 2023
Place of incorporation PRC
Percentage of effective ownership 51.00%
Principal Activities Sale of medical consumables
Huangshan Saitumofei Medical Treatment Technology Co., Ltd. [Member]  
Subsidiaries  
Date of incorporation /acquisition Apr. 30, 2024
Place of incorporation PRC
Percentage of effective ownership 100.00%
Principal Activities Research and development
[1] On July 27, 2022, Work Hangzhou acquired 51% of the shares of Shanghai Saitumofei for a cash consideration of RMB100,000. Since then, Shanghai Saitumofei has become a subsidiary of the Group. On May 24, 2024, Work Hangzhou and the other original shareholders of Shanghai Saitumofei (collectively, the “Original Shareholders”) entered into a Capital Injection Agreement with Tunxi District Huangshan City Leading Industry Incubation Fund Ltd. (“Huangshan Fund”). According to the agreement, Huangshan Fund agreed to invest RMB20 million in cash to obtain 13.33% newly issued shares of Shanghai Saitumofei. Following the capital investment by Huangshan Fund, the Group’s ownership interest in Shanghai Saitumofei was diluted to 44.2017%. However, on May 24, 2024, the Original Shareholders entered into a concerted action agreement (the “Concerted Action Agreement”), to ensure that the Group retains majority voting rights (collectively 86.67%) in Shanghai Saitumofei. Under the Concerted Action Agreement, if the Original Shareholders cannot reach a consensus, Work Hangzhou’s opinion shall prevail. The Concerted Action Agreement has no fixed term and is irrevocable unless all parties consent unanimously. As a result, the Group is still required to consolidate Shanghai Saitumofei in the reporting entity in the scope of ASC 810 Consolidation.